IMR Press / FBL / Volume 14 / Issue 8 / DOI: 10.2741/3431

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Advances in myogenic cell transplantation and skeletal muscle tissue engineering
Show Less
1 Regenerative Medicine Program and Center for Stem Cell and Gene Therapy, Ottawa Health Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada, K1H 8L6
2 Research Center on Aging, Faculty of Medicine, Department of Orthopedic Surgery, Universite de Sherbrooke, Quebec, Canada, J1H 4C3
Front. Biosci. (Landmark Ed) 2009, 14(8), 3012–3023; https://doi.org/10.2741/3431
Published: 1 January 2009
Abstract

Curative treatments are currently not available for people suffering from one of the many prevalent muscle myopathies. One approach to ameliorate these conditions relies on the cell-based transplantation of potential myogenic precursors, or more optimistically, the transfer of engineered skeletal muscle tissue. To date, clinical trials with myogenic stem cell transplantation have met with only modest success while the transplantation of engineered muscle tissue is at the earliest stages of development. Despite the slow progress, these studies have provided insights and avenues that will eventually lead to a powerful therapeutic tool.

Share
Back to top